Ambrisentan: a review of its use in pulmonary arterial hypertension

Citations Over TimeTop 14% of 2017 papers

Abstract

Pulmonary arterial hypertension (PAH) is a progressive disease defined by an elevation in pulmonary arterial pressure that can lead to right heart failure and death. Ambrisentan is a selective endothelin receptor antagonist approved for the treatment of idiopathic, heritable PAH and connective tissue disease-associated PAH. Ambrisentan has been shown to improve exercise capacity and hemodynamics with an acceptable side-effect profile. It has also proven to be safely used in combination with other PAH-specific medications, especially with phosphodiesterase-5 inhibitors. In the recent randomized trial, AMBITION, it was shown that upfront combination therapy of ambrisentan and tadalafil significantly decreased the risk of clinical failure compared with monotherapy. This review describes the drug profile of ambrisentan and its safety and efficacy in the treatment of PAH.

Related Papers

• → Initial dual oral combination therapy in pulmonary arterial hypertension(2016)142 cited
• → Simultaneous LC-MS analysis of plasma concentrations of sildenafil, tadalafil, bosentan, ambrisentan, and macitentan in patients with pulmonary arterial hypertension.(2020)14 cited
• → Plasma drug-concentrations in patients with pulmonary arterial hypertension on combination treatment(2016)1 cited
• [Pulmonary arterial hypertension: changing approaches to management].(2011)
• → Pharmacokinetic interactions in different combinations of specific pulmonary arterial hypertension treatment(2016)